The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting
Tóm tắt
Từ khóa
Tài liệu tham khảo
Senger, 1983, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid, Science, 219, 983, 10.1126/science.6823562
Ferrara, 1989, Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells, Biochem. Biophys. Res. Commun., 161, 851, 10.1016/0006-291X(89)92678-8
Rosenthal, 1990, Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor, Growth Fact., 4, 53, 10.3109/08977199009011010
Leung, 1989, Vascular endothelial growth factor is a secreted angiogenic mitogen, Science, 246, 1306, 10.1126/science.2479986
Keck, 1989, Vascular permeability factor, an endothelial cell mitogen related to PDGF, Science, 246, 1309, 10.1126/science.2479987
Asano, 1995, Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor, Cancer Res., 55, 5296
Maeda, 1989, Tumoritropic and lymphotropic principles of macromolecular drugs, Crit. Rev. Ther. Drug Carrier Sys., 6, 193
Maeda, 1991, SMANCS and polymer–conjugated macromolecular drugs, Adv. Drug Deliv. Rev., 6, 181, 10.1016/0169-409X(91)90040-J
H. MAEDA, Polymer conjugated macromolecular drugs for tumor-specific targeting, pp. 95–116 in Polymer Site Specific Pharmacotherapy (A. J. DOMB, ed.), Wiley, New York, USA (1994).
Maeda, 1992, Conjugation of anticancer agents and polymers, Bioconjugate Chem., 3, 351, 10.1021/bc00017a001
F. C. COURTICE, The origin of lipoprotein, pp. 89–126 in Lymph and Lymphatic System (H. S. MEYERSEN, Chairman) Charles C. Thomas, Springfield, IL, USA (1963).
Muggia, 1999, Doxorubicin–polymer conjugates, Clin. Cancer Res., 5, 7
Maeda, 1988, Purification and identification of [hydroxyprolyl 3] bradykinin in ascitic fluid from a patient with gastric cancer, J. Biol. Chem., 263, 16051, 10.1016/S0021-9258(18)37555-0
Matsumura, 1988, Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue, Jpn. J. Cancer Res., 79, 1327, 10.1111/j.1349-7006.1988.tb01563.x
Matsumura, 1991, Kinin-generating cascade in advanced cancer patients and in vitro study, Jpn. J. Cancer Res., 82, 732, 10.1111/j.1349-7006.1991.tb01910.x
Wu, 1998, Modulation of enhanced vascular permeability in tumors by bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger, Cancer Res., 58, 159
Maeda, 1994, Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both nitric oxide scavenger and nitric oxide synthase inhibitor, Jpn. J. Cancer Res., 85, 331, 10.1111/j.1349-7006.1994.tb02362.x
Doi, 1996, Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth, Cancer, 77, 1598, 10.1002/(SICI)1097-0142(19960415)77:8<1598::AID-CNCR27>3.0.CO;2-U
Reichman, 1986, Effect of steroids and nonsteroid anti-inflammatory agents on vascular permeability in a rat glioma model, J. Neurosurg., 65, 233, 10.3171/jns.1986.65.2.0233
J. WU, T. AKAIKE, T. SAWA, A. OKUYAMA and H. MAEDA, Peroxynitrite and its activated matrix metalloproteinases involved in enhancement of vascular permeability in solid tumor, Jpn. J. Cancer Res. (in press) (2000).
Suzuki, 1987, Medial regression and its functional significance in tumor–supplying host arteries, Cancer, 59, 444, 10.1002/1097-0142(19870201)59:3<444::AID-CNCR2820590316>3.0.CO;2-5
Skinner, 1991, Microvascular architecture of experimental colon tumors in the rats, Cancer Res., 50, 2411
Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy, Cancer Res., 46, 6387
Iwai, 1984, Use of oily contrast medium for selective drug targeting to tumor, Cancer Res., 44, 2115
Noguchi, 1998, Early phase tumor accumulation of macromolecules, Jpn. J. Cancer Res., 89, 307, 10.1111/j.1349-7006.1998.tb00563.x
Iwai, 1987, Tumor targeting by arterial administration of lipids, Anticancer Res., 7, 321
Maeda, 1984, Tailor-making of protein drugs by polymer conjugation for tumor targeting, J. Prot. Chem., 3, 181, 10.1007/BF01040499
H. MAEDA, Y. MATSUMURA, T. ODA and K. SASAMOTO, Cancer selective macromolecular therapeutics: tailoring of antitumor protein drugs, pp. 353–382 in Protein Tailoring for Food and Medical Uses (R. E. FEENEY and J. R. WHITAKER, eds.), Marcel Dekker Inc., New York, USA, (1986).
Maeda, 1979, A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic, Int. J. Pept. Protein Res., 14, 81, 10.1111/j.1399-3011.1979.tb01730.x
Maeda, 1985, Conjugation of poly(styrene-co-maleic acid) derivatives to antitumor protein neocarzinostatin, J. Med. Chem., 28, 455, 10.1021/jm00382a012
Larson, 1978, Mechanism of localization of gallium-67 in tumors, Semin. Nucl. Med., 8, 193, 10.1016/S0001-2998(78)80028-2
Seymour, 1995, Influence of molecular weight on passive tumor accumulation of a soluble macromolecular drug carrier, Eur. J. Cancer, 31A, 766, 10.1016/0959-8049(94)00514-6
H. MAEDA and Y. KOJIMA, Polymer-drug conjugates, pp. 753–767 in Desk Reference of Functional Polymers: Synthesis and Applications (R. ASHARDY, ed.) Am. Chem. Society, Washington, DC, USA (1997).
Sakata, 1996, Bradykinin generation triggered by Pseudomonas protease facilitates invasion of the systemic circulation by Pseudomonas aeruginosa, Microbiol. Immunol., 40, 415, 10.1111/j.1348-0421.1996.tb01088.x
Maruo, 1998, Involvement of bradykinin generation in intravascular dissemination of Vibrio vulnificus and prevention of invasion by a bradykinin antagonist, Infect. Immun., 66, 866, 10.1128/IAI.66.2.866-869.1998
Maeda, 1999, Kallikrein-kinin in infection and cancer, Immunopharmacology, 43, 115, 10.1016/S0162-3109(99)00104-6
Okamoto, 1997, Activation of human neutrophil precollagenase by nitrogen dioxide and peroxynitrite, Arch. Biochem. Biophys., 342, 261, 10.1006/abbi.1997.0127
Maeda, 1998, Human matrix metalloprotease activation by insults of bacterial infection involving proteases and free radicals, Biol. Chem., 379, 193, 10.1515/bchm.1998.379.2.193
Moreno, 1992, Inactivation of α1-protease inhibitor by peroxynitrite, Chem. Res. Toxicol., 5, 425, 10.1021/tx00027a017
Suzuki, 1981, A new approach to cancer chemotherapy, J. Natl. Cancer Inst., 67, 663
Li, 1993, Augmentation of tumor delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure, Brit. J. Cancer, 67, 975, 10.1038/bjc.1993.179
Hori, 2000, Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril, hydrochloride, Jpn. J. Cancer Res., 91, 261, 10.1111/j.1349-7006.2000.tb00940.x
Gallo, 1998, Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer, J. Natl. Cancer Inst., 90, 587, 10.1093/jnci/90.8.587
Garcia-Cardena, 1998, Is there a role for nitric oxide in tumor angiogenesis (Editorial), J. Natl. Cancer Inst., 90, 560, 10.1093/jnci/90.8.560
Jackson, 1997, The codependence of angiogenesis and chronic inflammation, FASEB J., 11, 457, 10.1096/fasebj.11.6.9194526
Konno, 1984, Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium, Cancer, 54, 2367, 10.1002/1097-0142(19841201)54:11<2367::AID-CNCR2820541111>3.0.CO;2-F
Konno, 1983, Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma, Eur. J. Cancer Clin. Oncol., 19, 1053, 10.1016/0277-5379(83)90028-7
Maki, 1985, Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium, Cancer, 56, 751, 10.1002/1097-0142(19850815)56:4<751::AID-CNCR2820560409>3.0.CO;2-Y
Tsuchiya, 2000, Tumor-targeted chemotherapy with SMANCS in Lipiodol for renal cell carcinoma, Urology, 55, 495, 10.1016/S0090-4295(99)00537-3
H. MAEDA and Y. MIYAMOTO, SMANCS approach – Oily formulation of protein drugs for arterial injection and oral administration, pp. 221–247 in Drug Absorption Enhancement: Concepts, Possibilities, Limitations, and Trends (A. G. DE BOER, ed.) Harwood Academic Publishers, Chur, Switzerland (1994).
T. KONNO and H. MAEDA, Targeting chemotherapy of hepatocellular carcinoma: arterial administration of SMANCS/Lipiodol, pp. 343–352 in Neoplasms of the Liver (K. OKUDA, K.G. ISHAK, eds.), Springer-Verlag, Tokyo, Berlin, New York (1987).
Konno, 1992, Targeting chemotherapy for hepatoma, Eur. J. Cancer, 28, 403, 10.1016/S0959-8049(05)80063-2
H. MAEDA and T. KONNO, Metamorphosis of neocarzinostatin to SMANCS: chemistry, biology, pharmacology and clinical effect of the first prototype anticancer polymer therapeutic, pp. 227–267 in Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug (H. MAEDA, K. EDO and N. ISHIDA, eds.) Springer-Verlag, Tokyo, Berlin, New York (1997).
Maeda, 2000, Tumor vascular permeability and the EPR effect in macromolecular therapeutics, J. Control. Release, 65, 271, 10.1016/S0168-3659(99)00248-5
Vasey, 1999, Phase I Clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylaminde copolymer doxorubicin], Clin. Cancer Res., 5, 83